CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER).
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
| Metabolism | Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis. |
| Excretion | The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination. |
| Half-life | Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture. |
| Protein binding | Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific. |
| Volume of Distribution | Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture. |
| Bioavailability | Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes. |
| Onset of Action | Intravenous infusion: immediate upon administration. Clinical effects such as serum glucose elevation and amino acid incorporation begin within minutes. Full metabolic effects (e.g., nitrogen balance improvement) occur over hours to days with continuous infusion. |
| Duration of Action | Intravenous infusion: duration depends on infusion rate; continuous infusion provides sustained effect. Metabolic effects persist for several hours post-infusion as nutrients are cleared. Clinical notes: prolonged infusion (e.g., 24 hours) is typical for parenteral nutrition to maintain metabolic support. |
| Molecular Weight | Amino acids range ~75–204 Da; dextrose 180.16 Da |
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-59 mL/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 mL/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 mL/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed. |
| Pediatric use | Dose based on weight (kg) and caloric needs. Typical: 10-15 mL/kg/day initially, titrate to 20-30 mL/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants. |
| Geriatric use | Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 mL/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended. |
| 1st trimester | Amino acids and dextrose are essential nutrients; no known teratogenic risk. Use only if clearly needed for maternal malnutrition. |
| 2nd trimester | Generally considered safe when used for maternal nutritional support. Monitor fluid and electrolyte balance. |
| 3rd trimester | Safe for maternal parenteral nutrition. May cause fluid overload or electrolyte disturbances if not carefully monitored. |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER).
| Placental transfer | Amino acids cross the placenta via active transport; dextrose crosses by facilitated diffusion. Both are endogenous substances. |
| Breastfeeding | Amino acids and dextrose are normal constituents of breast milk. No known adverse effects from intravenous administration. Use with caution in nursing mothers as safety not fully established. |
| Lactation Rating | L2: Safer |
| Teratogenic Risk | CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor. |
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes (Na, K, Ca, Mg, phosphate), fluid balance, and renal function. Fetal monitoring for growth and well-being if used long-term or in high doses. |
| Fertility Effects | No known effects on fertility. Components are essential nutrients and do not impair reproductive function. |
■ FDA Black Box Warning
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
| Serious Effects |
Severe electrolyte disturbancesSevere fluid overloadAnuriaKnown hypersensitivity to any componentSevere hepatic failure (for amino acid solutions)Maple syrup urine disease (may contain branched-chain amino acids)
| Precautions | Monitor fluid balance, electrolyte concentrations, and acid-base status, Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis, Hepatic and renal impairment require dose adjustment, Contains aluminum which may be toxic with prolonged use, Use with caution in patients with heart failure or pulmonary edema |
| Food/Dietary | Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content. |
| Clinical Pearls | This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients. |
| Patient Advice | This medication is given intravenously to provide nutrition when you cannot eat. · Report any signs of infection at the IV site: redness, swelling, pain, or fever. · You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function. · Do not suddenly stop the infusion without consulting your healthcare provider. · Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar). |
Loading safety data…